Related Experiment Video

Updated: Sep 29, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K

Circular RNA circ_0001006 aggravates cardiac hypertrophy via miR-214-3p/PAK6 axis

Xuefeng Lin1,2,3,4,5,6, Liqin Zhang6, Wei Zhang7

  • 1Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi 710061, PR China.

Aging
|March 20, 2022
PubMed

Insights

Circular RNA hsa_circ_0001006 (circ_0001006) worsens cardiac hypertrophy by inhibiting miR-214-3p, which increases PAK6 levels. This finding reveals a novel mechanism in heart disease progression.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cardiovascular Research

Background:

  • Circular RNAs (circRNAs) regulate gene expression in various biological processes.
  • The specific role of circRNAs in the development of heart disease remains largely unexplored.
  • Cardiac hypertrophy is a significant risk factor for heart failure.

Purpose of the Study:

  • To investigate the role and underlying mechanism of circRNAs in cardiac hypertrophy.
  • To identify specific circRNAs involved in the pathological process of cardiac hypertrophy.

Main Methods:

  • Upregulation of circRNA hsa_circ_0001006 (circ_0001006) was observed in cardiac hypertrophy models.
  • Gain-of-function and knockdown experiments demonstrated circ_0001006's role in cardiomyocyte hypertrophy.
  • RNA pull-down and dual-luciferase reporter assays were used to elucidate molecular interactions.

Main Results:

  • circ_0001006 was upregulated in cardiac hypertrophy and induced hypertrophy in cardiomyocytes.
  • Knockdown of circ_0001006 alleviated angiotensin II-induced cardiomyocyte hypertrophy.
  • circ_0001006 directly binds to miR-214-3p and inhibits its function.
  • miR-214-3p targets the PAK6 gene, and circ_0001006 blocks this interaction.

Conclusions:

  • circRNA_0001006 exacerbates cardiac hypertrophy.
  • The mechanism involves the suppression of miR-214-3p, leading to increased PAK6 expression.
  • circ_0001006 represents a potential therapeutic target for cardiac hypertrophy.
Abstract

Keywords:
cardiac hypertrophycircular RNAsgene expressionheart diseasemiRNA

More Related Videos

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions10:27

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

Published on: October 21, 2022

1.7K
Identification of Circular RNAs using RNA Sequencing08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.4K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
76
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
64
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K